跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
IS-001
首页
药物
IS-001
IS-001
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ORAL PCLX-001 IN THE TREATMENT OF HUMAN CANCER
申请人: PACYLEX PHARMACEUTICALS INC
优先权: 2022
CN
EP
US
3 件公开
TAT- 001 and methods of assessing and treating cancer
申请人: CAPRION PHARMACEUTICALS INC
优先权: 2006
US
Nanocrystalline catalyst and preparation method thereof, and preparation method of propylene oxide
申请人: UNIV SCIENCE & TECHNOLOGY CHINA
优先权: 2018
CN
ORAL PCLX-001 IN THE TREATMENT OF HUMAN CANCER
申请人: PACYLEX PHARMACEUTICALS INC
优先权: 2023
WO
Ginseng PgRb1-057-001 gene and application thereof
申请人: UNIV JILIN AGRICULTURAL
优先权: 2022
CN
Application of compound ICG-001 in preparing hypertension treating medicines
申请人: NANFANG HOSPITAL SOUTHERN MEDICAL UNIV
优先权: 2014
CN
2 件公开
Application of RRx-001 combined with phenatinib in preparation of medicine for treating extracorporeal NK/T cell lymphoma
申请人: AFFILIATED HOSPITAL XUZHOU MEDICAL UNIV
优先权: 2025
CN
Use of compound ICG-001 in preparation of medicine for treating hypertension
申请人: NANFANG HOSPITAL SOUTHERN MEDICAL UNIV
优先权: 2014
CN
药物
反馈